Market Overview

UPDATE: Oppenheimer Holdings Downgrades Celgene Corporation to Perform, Removes PT

Share:
Related CELG
Vetr Crowd Downgrades Celgene
The Week Ahead: IPOs, Earnings, And FDA Actions Provide Catalysts
Celgene: Juno To Rejuvenate The Pipeline? (Seeking Alpha)

In a report published Monday, Oppenheimer Holdings downgraded its rating on Celgene Corporation (NASDAQ: CELG) from Outperform to Perform, and removed its $77.00 price target.

Oppenheimer noted, “We are downgrading Celgene from Outperform to Perform and removing our $77 price target. We believe that the company is trading in line with its peers (15x our 2014E GAAP EPS of $5.36). Although we estimate Revlimid will grow 14%/yr over the next three years, we believe that Celgene is likely to make several substantial acquisitions over the next 1-2 years in order to extend top-line growth beyond Revlimid. We analyzed Celgene's acquisitions of Pharmion, Abraxis, and Gloucester and came to the conclusion that these acquisitions had limited, if any, return based on the acquisition price. Given the recent strong performance for the entire biotech sector, we believe that it will be more difficult for Celgene to find good acquisitions.”

Celgene Corporation closed on Friday at $78.42.

Latest Ratings for CELG

DateFirmActionFromTo
Jan 2018Bank of AmericaDowngradesBuyNeutral
Dec 2017BernsteinDowngradesOutperformMarket Perform
Dec 2017Deutsche BankInitiates Coverage OnHold

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Oppenheimer HoldingsAnalyst Color Downgrades Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!